Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma of the uterine cervix~  * Advanced disease (stage IVB)~ * Persistent or recurrent disease~* No available curative treatment options~* Measurable disease by physical examination, chest x-ray, CT scan, or MRI~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* GOG 0-2~Life expectancy~* More than 6 months~Hematopoietic~* Absolute neutrophil count \> 1,500/mm\^3~* Platelet count \> 100,000/mm\^3~* Hemoglobin \> 8 g/dL~Hepatic~* Bilirubin normal~* SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase normal OR~* Alkaline phosphatase ≤ 4 times ULN AND SGOT and SGPT normal~Renal~* Creatinine \< 1.5 times ULN~Other~* No other invasive malignancy within the past 5 years~* No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~* No peripheral neuropathy \> grade 1~* No other concurrent malignancy except curatively treated non-melanoma skin cancer~* No other serious medical or psychiatric illness that would preclude giving informed consent or limit survival~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent biologic therapy~Chemotherapy~* No more than 2 prior chemotherapy regimens~  * One sensitizing chemotherapy regimen during radiotherapy AND 1 regimen for recurrent disease are considered 2 regimens~* At least 4 weeks since prior chemotherapy~* No prior docetaxel~* No prior carboplatin~* No other concurrent chemotherapy~Endocrine therapy~* At least 4 weeks since prior hormonal therapy~Radiotherapy~* See Chemotherapy~* At least 4 weeks since prior radiotherapy~* No concurrent radiotherapy~Surgery~* At least 3 weeks since prior major surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).